Debug Stats | ### Total Build Time: 19 ms 43.907 KB CONCEPT_NAME gt=0 Completed: 0 ms rowSize= 382 bytesCONCEPT_SOLR_HIT_STATS gt=0 Completed: 0 ms rowSize= 14 bytesCONCEPT_DEFINITION gt=0 Completed: 0 ms rowSize= 275 bytes- Skipping details on:
CONCEPT_SYNONYM gt=NONE 0 Completed: 0 ms rowSize= 0 bytes - Skipping details on:
CONCEPT_TEXT gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_SEMANTIC_TYPE gt=1 ms Completed: 1 ms rowSize= 14 bytes- Skipping details on:
CONCEPT_NAMESPACE gt=NONE 0 Completed: 0 ms rowSize= 0 bytes CONCEPT_PARENTS gt=0 Completed: 0 ms rowSize= 7 bytesCONCEPT_CHILDREN gt=0 Completed: 0 ms rowSize= 8 bytesCONCEPT_ANCESTRAL_ROOTS gt=0 Completed: 0 ms rowSize= 15 bytesCONCEPT_RELATIONSHIPS gt=4 ms Completed: 4 ms rowSize= 7.954 KBCONCEPT_GENES gt=13 ms Completed: 13 ms rowSize= 34.065 KBCONCEPT_XREFS gt=0 Completed: 0 ms rowSize= 1.176 KBCONCEPT_ANCILLARY gt=1 ms Completed: 1 ms rowSize= 14 bytes- Reload Stats
|
Genes (22)
Species: human : 20 mouse : 2 | |
Mouse | DRG1 | 4733 | developmentally regulated GTP binding protein 1 | Functional studies revealed that overexpression of Drg-1 in metastatic colon cancer cells reduced in vitro invasion through Matrigel and suppressed in vivo liver metastases in nude mice. | Mouse | SMAD3 | 4088 | SMAD family member 3 | Smad3 mutant mice develop metastatic colorectal cancer. | Human | GGT2 | 728441 | gamma-glutamyltransferase 2 | The evolution of metastatic colorectal cancer in patients who have had surgical treatment for a primary lesion was studied in relation the progressive changes in the blood levels of carcinembryonic antigen (CEA), to gamma glutamyl transpeptidase (GGT) and routine liver function tests (LFTs). | Human | PMEPA1 | 56937 | prostate transmembrane protein, androgen induced 1 | PMEPA1, a transforming growth factor-beta-induced marker of terminal colonocyte differentiation whose expression is maintained in primary and metastatic colon cancer. | Human | LASS2 | 29956 | | The sections from paraffin-embedded blocks of human cancer (52 cases of breast carcinoma and 41 cases of colon cancer) were stained, showing strongly positive in non-metastatic tumor and weakly positive or negative in metastatic tumor; the strongly positive rate of TMSG-1 expression in human cancers were, respectively, 36%, 7.4%, 52.4%, and 35% in non-metastatic and metastatic breast cancer and non-metastatic and metastatic colon cancer (p = 0.02). | Human | PTP4A3 | 11156 | protein tyrosine phosphatase type IVA, member 3 | In metastatic colorectal cancer lesions, high expression of PRL-3 was frequently detected (liver, 91.3%; lung, 100%). | Human | GPA33 | 10223 | glycoprotein A33 (transmembrane) | A33 is found in 95% of primary and metastatic colorectal cancers, with uniform expression throughout the tumors in most cases. | Human | TIMP2 | 7077 | TIMP metallopeptidase inhibitor 2 | Exploration of TIMP-2 expression is valuable for the discrimination between macroscopically localized and metastatic colorectal cancer, but it cannot predict which of the potentially cured patients are likely to have micrometastases. | Human | TIAM1 | 7074 | T-cell lymphoma invasion and metastasis 1 | RESULTS AND CONCLUSION: Two new genes (TIAM1 and NM23H1) with potential relation to metastatic colorectal cancer were identified. | Human | THBS2 | 7058 | thrombospondin 2 | Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. | Human | TGFB2 | 7042 | transforming growth factor, beta 2 | By immunohistochemistry in-vivo, we confirmed COX2 and TGFB2 expression in cancer-associated fibroblasts in metastatic colon cancer. | Human | NME1 | 4830 | NME/NM23 nucleoside diphosphate kinase 1 | Expression of nm23 increased during early stages of colon carcinogenesis and remained increased in metastatic colon cancer. MATERIALS AND METHODS: Archival tissues of 41 non metastatic colorectal cancers were histopathologically evaluated and stained with monoclonal antibodies versus Nm23-H1 and CD44v6. Overexpression of nm23 protein assessed by color video image analysis in metastatic colorectal cancer: correlation with reduced patient survival. | Human | DRG1 | 4733 | developmentally regulated GTP binding protein 1 | Stable transfection of the SW620 metastatic colon cancer cell line with Drg-1 cDNA induced morphological changes consistent with differentiation and up-regulated the expression of several colonic epithelial cell differentiation markers (alkaline phosphatase, carcinoembryonic antigen, and E-cadherin). We performed this study to evaluate the role of Drg1 in a large cohort of patients with metastatic colorectal cancer who were irinotecan naive. EXPERIMENTAL DESIGN: We examined Drg1 expression by immunohistochemistry in 131 patients with metastatic colorectal cancer enrolled in a clinical trial of adjuvant fluorouracil-based therapy from 1991 to 1995. | Human | LGALS1 | 3956 | lectin, galactoside-binding, soluble, 1 | RESULTS: Introduction of galectin 3 antisense into metastatic colon cancer cells (LSLiM6, HM7) resulted in a significant reduction in galectin 3-specific messenger RNA and total and cell surface galectin 3 protein. | Human | LCK | 3932 | lymphocyte-specific protein tyrosine kinase | The Lck protein (p56(lck)), a src family tyrosine kinase that is essential for T cell development and function, is aberrantly expressed in metastatic colon cancers. | Human | GUCY2C | 2984 | guanylate cyclase 2C (heat stable enterotoxin receptor) | GCC:B10 mAb, generated against human guanylyl cyclase C, a membrane-associated receptor and a potential marker for metastatic colon cancer, recognizes the cognate peptide epitope HIPPENIFPLE and its two contiguous mimotopes, HIPPEN and ENIFPLE, specifically and reversibly. Guanylyl cyclase C is a sensitive and specific biomarker for metastatic colorectal cancer. | Human | FGF7 | 2252 | fibroblast growth factor 7 | PURPOSE: To evaluate the safety of recombinant human keratinocyte growth factor (KGF) when administered with fluorouracil (FU) in patients with metastatic colorectal cancer. | Human | ERCC1 | 2067 | excision repair cross-complementing rodent repair deficiency, complementation group 1 (includes overlapping antisense sequence) | The ERCC1 polymorphism was analyzed in the normal tissue of all patients.RESULTS: Twenty (22%) were homozygous for AAC codon (C/C genotype), 30 were (33%) homozygous for AAT codon (T/T genotype), and 41 (45%) were heterozygous (C/T genotype). PURPOSE: The aim of our study was to assess whether the polymorphism of the nucleotide excision repair enzyme, excision repair cross-complementing rodent repair deficiency, complementation group 1 (ERCC1), had an effect on the tumor response in patients treated with standard chemotherapy regimens for a metastatic colorectal cancer. CONCLUSION: These data suggest that intratumoral ERCC1 mRNA and TS mRNA expression levels are independent predictive markers of survival for 5-FU and oxaliplatin combination chemotherapy in 5-FU-resistant metastatic colorectal cancer. PURPOSE: To test the hypotheses of whether the relative mRNA expression of the thymidylate synthase (TS) gene and the excision cross-complementing (ERCC1) gene are associated with response to and survival of fluorouracil (5-FU)/oxaliplatin chemotherapy in metastatic colorectal cancer. This change results in a decreased ERCC1 gene expression, which impairs repair activity.EXPERIMENTAL DESIGN: Ninety-one patients with a median age of 55.1 years treated for a metastatic colorectal cancer were included in our retrospective study. | Human | DUT | 1854 | deoxyuridine triphosphatase | To examine the association between dUTPase expression and response to 5-FU-based chemotherapy and overall survival, we initiated a retrospective study including tumor specimens from 20 patients who had received protracted infusion of 5-FU and leucovorin for treatment of metastatic colon cancer. To examine the association between dUTPase expression and response to 5-FU-based chemotherapy and overall survival, we initiated a retrospective study including tumor specimens from 20 patients who had received protracted infusion of 5-FU and leucovorin for treatment of metastatic colon cancer. | Human | DAB2 | 1601 | Dab, mitogen-responsive phosphoprotein, homolog 2 (Drosophila) | METHODS: DOC-2 expression was analyzed by Northern blot analysis, hybridization, and immunohistochemistry in 27 primary and metastatic colorectal cancers and in 15 normal colon tissues in correlation with clinicopathologic data. RESULTS: Northern blot analysis demonstrated a decrease of DOC-2 messenger RNA levels in primary and metastatic colorectal cancers compared with normal controls. | Human | ANGPT2 | 285 | angiopoietin 2 | Hepatic expression of ANG2 RNA in metastatic colorectal cancer. | Human | ANGPT1 | 284 | angiopoietin 1 | Thus, Ang-1 could potentially serve as an antineoplastic or anti-permeability agent for patients with metastatic colorectal cancer. |
|